Standout Papers

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line ther... 2015 2026 2018 2022 328
  1. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial (2015)
    Nick Thatcher, Fred R. Hirsch et al. The Lancet Oncology

Immediate Impact

5 from Science/Nature 98 standout
Sub-graph 1 of 18

Citing Papers

Switching between the [2π+2σ] and Hetero‐[4π+2σ] Cycloaddition Reactivity of Bicyclobutanes with Lewis Acid Catalysts Enables the Synthesis of Spirocycles and Bridged Heterocycles
2024 Standout
Optimized inhaled LNP formulation for enhanced treatment of idiopathic pulmonary fibrosis via mRNA-mediated antibody therapy
2024 Standout
2 intermediate papers

Works of Rinat Galiulin being referenced

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
2015 Standout
International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
2012

Author Peers

Author Last Decade Papers Cites
Rinat Galiulin 367 385 37 135 7 550
Andrzej Każarnowicz 414 302 35 148 14 569
V. Gorbounova 355 392 24 122 7 508
Catherine Chodkiewicz 385 267 28 159 10 636
Eugene Paschold 421 339 30 152 12 581
Max Hallin 271 255 60 359 6 622
Robert Weaver 289 371 23 88 8 531
Maren L. Grazzini 247 273 35 361 8 623
Carina Hillenbach 375 314 33 110 11 617
Amy Krie 254 168 38 167 10 504
Christa G.M. Gadellaa-van Hooijdonk 340 117 25 104 7 491

All Works

Loading papers...

Rankless by CCL
2026